ICON 9-an international phase III randomized study to evaluate the efficacy of maintenance therapy with olaparib and cediranib or olaparib alone in patients with relapsed platinum-sensitive ovarian cancer following a response to platinum-based chemotherapy

Elyashiv, O; Ledermann, J; Parmar, G; Farrelly, L; Counsell, N; Feeney, A; El-Khouly, F; Macdonald, I; Neto, A; Arthur-Darkwa, E; Burnett, E; Jayson, GC; Mileshkin, L; Gourley, C; Nicum, S

Author(s): Elyashiv, O; Ledermann, J; Parmar, G; Farrelly, L; Counsell, N; Feeney, A; El-Khouly, F; Macdonald, I; Neto, A; Arthur-Darkwa, E; Burnett, E; Jayson, GC; Mileshkin, L; Gourley, C; Nicum, S;
Details: Publication Year 2021-01,Volume 31,Issue #1,Page 134-138
Journal Title: International Journal of Gynecological Cancer
Publication Type: Protocol
Abstract: BACKGROUND: Two novel biological agents-cediranib targeting angiogenesis, and olaparib targeting DNA repair processes-have individually led to an improvement in ovarian cancer control. The aim of ICON9 is to investigate the combination of cediranib and olaparib maintenance in recurrent ovarian cancer following platinum-based therapy. PRIMARY OBJECTIVE: To assess the efficacy of maintenance treatment with olaparib in combination with cediranib compared with olaparib alone following a response to platinum-based chemotherapy in women with platinum-sensitive ovarian, fallopian tube or peritoneal cancer during first relapse. STUDY HYPOTHESIS: Maintenance therapy with cediranib and olaparib in combination is associated with improved patient outcomes compared with olaparib alone. TRIAL DESIGN: International phase III randomized controlled trial. Following a response to platinum-based chemotherapy patients are randomized 1:1 to either oral olaparib and cediranib (intervention arm) or oral olaparib alone (control arm). MAJOR INCLUSION CRITERIA: Patients with a known diagnosis of high grade serous or endometrioid carcinoma of the ovary, fallopian tube or peritoneum, progressing more than 6 months after first-line platinum-based chemotherapy, who have responded to second-line platinum-based chemotherapy. PRIMARY ENDPOINTS: Progression-free and overall survival. Co-primary endpoints to be assessed using a fixed-sequence gatekeeping approach: (1) progression-free survival, all patients; (2) progression-free survival, BRCA wild type; (3) overall survival, all patients; (4) overall survival, BRCA wild type. SAMPLE SIZE: 618 patients will be recruited. ESTIMATED DATES FOR COMPLETING ACCRUAL AND PRESENTING RESULTS: Accrual is expected to be completed in 2024 with presentation of results in 2025. TRIAL REGISTRATION: ClinicalTrials.gov: NCT03278717.
Keywords: Adult; Clinical Trials, Phase III as Topic; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Neoplasm Recurrence, Local/*drug therapy; Ovarian Neoplasms/*drug therapy; Phthalazines/*administration & dosage/adverse effects; Piperazines/*administration & dosage/adverse effects; Poly(ADP-ribose) Polymerase Inhibitors/*administration & dosage/adverse effects; Quinazolines/*administration & dosage/adverse effects; Randomized Controlled Trials as Topic; Survival Analysis
Department(s): Medical Oncology
PubMed ID: 33097567
Publisher's Version: https://doi.org/10.1136/ijgc-2020-002073
Terms of Use/Rights Notice: Refer to copyright notice on published article.

Creation Date: 2026-09-24 05:52:45

Last Modified: 2026-09-24 05:53:56